Morepen Laboratories Limited

As of June 30, 2026, Morepen Laboratories Limited carries a market capitalization of 32.41B, placing it among publicly traded companies globally. Its enterprise value stands at 32.41B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Morepen Laboratories Limited has 547.95M shares outstanding.

As of June 30, 2026, Morepen Laboratories Limited trades at a trailing price-to-earnings ratio of 23.20.

As of June 30, 2026, Morepen Laboratories Limited trades at an EV/EBITDA multiple of 15.45 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.66 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 18.62 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 32.41B versus a market cap of 32.41B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 6.30M in revenue per employee across its workforce of 3,097.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Morepen Laboratories Limited recorded 383.45M in income tax expense. That works out to an effective tax rate of 21.43, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.79B, leaving 1.41B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Morepen Laboratories Limited's stock has gained approximately 139.88% over the past 52 weeks. The 50-day moving average sits at 112.80, while the 200-day moving average is 62.37.

Over the twelve months ended June 30, 2026, Morepen Laboratories Limited generated 19.51B in revenue and converted that into 1.41B in net income, yielding earnings per share of 2.55. EBITDA reached 2.10B, while operating income came in at 1.48B.

Over the twelve months ended June 30, 2026, Morepen Laboratories Limited posted a gross margin of 39.52, reflecting its pricing power and cost economics. The operating margin of 7.60 and net profit margin of 7.20 provide insight into operational efficiency.

Morepen Laboratories Limited's most recent stock split took place on November 7, 2000 with a 1:5 split ratio.